Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors Patients with advanced malignancy (N = 385) were randomly assigned ...

Pfizer won the backing of a US Food and Drug Administration advisory panel yesterday to extend the use of its anti-clotting drug Fragmin to include the prevention of venous thromboembolism (VTE) in ...

NEW YORK (MedscapeWire) Nov 30 — Pharmacia Corporation has initiated PREVENT (PRospective EValuation of Dalteparin Efficacy for Prevention of VTE in Immobilized PatieNts Trial) to study the safety and ...

Please provide your email address to receive an email when new articles are posted on . Extended treatment with oral edoxaban appeared comparable to subcutaneous dalteparin in safety and effectiveness ...

For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), ...

The US Food and Drug Administration (FDA) approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in paediatric ...

Results of a study comparing apixaban with low-molecular-weight heparin as a treatment to prevent recurrent blood clots in patients with cancer may assuage some of the concern about the bleeding risk ...

Patients aged over 18 years with WHO performance status 0–2 and histologically proven advanced malignancy refractory to conventional treatment who gave written informed consent were eligible for the ...

The introduction of low-molecular-weight heparins (LMWHs) was a watershed event in the treatment of thrombotic disorders. LMWHs differ from unfractionated heparin (UFH) in that they have excellent ...

To the Editor: The Prophylaxis for Thromboembolism in Critical Care Trial (PROTECT; ClinicalTrials.gov number, NCT00182143) investigators (April 7 issue) 1 report a significantly reduced incidence of ...